Muscle diseases come in a variety of forms. Among the more common conditions are muscle wasting, which can occur in cancer patients and the elderly. But there are also hundreds of genetically caused muscle diseases as well as local muscle defects that altogether affect more than 15 million in Europe.
MyoPax is a muscle stem cell-producing platform for the treatment of muscle defects and genetic muscular dystrophies. It combines its proprietary first-in-class muscle stem cell manufacturing technology with CRISPR/Cas9-based gene repair. The first muscle stem cell product will enter a clinical trial soon (beginning of 2022). The founding of MyoPax as spin-off of the Charité University Medicine and the Max Delbrück Center for Molecular Medicine in Berlin is planned for this year.
The group is a pre-spinout group at the Max Delbrueck Center and Charité – Universitätsmedizin in Berlin, Germany, whose work is suppored by SPARK Berlin. In this episode of BioInnovation Spotlight @ LifeScience ORG Verena talks about the impact of muscle disease, MyoPax's technology and how it works, and their plans to spin out.